[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"arteriovenous-malformation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:arteriovenous-malformation":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,55,83,114,141],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":33,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":4},"100642579","case-specific-health-care-professional-clinical-survey-for-concerto-versa-detachable-coils-100642579",false,"NCT07639853","Case-Specific Health Care Professional Clinical Survey for Concerto Versa™ Detachable Coils","Inclusion Criteria:\n\n1. Patient treated with Concerto Versa™ Detachable Coil is age ≥ 22 years at the time of procedure.\n2. Use of Concerto Versa™ Detachable Coil in accordance with the device labeling.\n3. Reporting of case within 72 hours of index procedure.","ALL","22 Years",{"count":18,"type":19},30,"ESTIMATED","OBSERVATIONAL","The purpose of the Case-Specific Health Care Professional (HCP) Clinical Survey for Concerto Versa™ Detachable Coils, also known as the Concerto Versa HCP Clinical Assessment, is to collect early clinical data from HCPs to assess clinical safety and performance of the Concerto Versa™ Detachable Coils, when used in accordance with approved device labeling per the Instructions for Use (IFU). Data collected will generate clinical evidence to quantitatively assess clinical safety and device performance for the purpose of obtaining European Union Medical Device Regulation (EU MDR) approval.",[23,24,25,26,27,28,29,30,31,32],"Arteriovenous Malformation","Gastrointestinal Bleed","Gastric Varices","Hemorrhoid","Pelvic Venous Disorders","Peripheral Aneurysms","Portal Vein Embolization","Type II Endoleak","Varicocele","Hemorrhage",[34,35,36,37,38,39,40,41,42],"Peripheral Vascular Disease","Vascular Disease","Arterial Embolization","Arteriovenous Embolization","Venous Embolization","Embolization Coils","Peripheral Embolization Coils","Peripheral Arterial Disease","Embolization","NOT_YET_RECRUITING","2026-06-11",{"date":46,"type":47},"2026-06-15","ACTUAL",{"date":49,"type":19},"2026-07",{"date":51,"type":19},"2026-11",{"name":53,"class":54},"Medtronic Endovascular","INDUSTRY",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":15,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":4},"100604968","the-clinical-application-of-peripheral-embolization-coil-systems-in-arteriovenous-embolization-within-the-peripheral-vasculature-100604968","NCT07156409","The Clinical Application of Peripheral Embolization Coil Systems in Arteriovenous Embolization Within the Peripheral Vasculature","A Prospective, Multicenter, Single-Arm Target Value Study Evaluating the Safety and Effectiveness of a Peripheral Embolization Coil System for the Treatment of Arteriovenous Embolization in the Peripheral Vasculature in a Real-World Setting","Inclusion Criteria:\n\n1. Aged 18 to 75 years (inclusive), regardless of gender;\n2. Patients diagnosed preoperatively via imaging (including but not limited to ultrasound, CTA, MRA, DSA, etc.) with peripheral arteriovenous conditions requiring embolization therapy;\n3. The visually estimated normal reference diameter of the target vessel is ≥ 3mm;\n4. Patients or their legally authorized representatives are capable of understanding the study objectives, voluntarily participating in this study, providing signed informed consent, and able to comply with follow-up.\n\nExclusion Criteria:\n\n1. The target vessel requires the concurrent use of other embolic materials (e.g., Gelfoam, embolic microspheres, liquid embolic agents, etc.);\n2. Known definite history of allergy to platinum, tungsten metals, and\u002For any component of the investigational product;\n3. Subjects with pre-existing severe cardiac, hepatic, renal, respiratory diseases, or coagulation disorders who are unsuitable for anesthesia or endovascular surgical treatment;\n4. High-flow arteriovenous fistulas that may cause migration of the embolic material;\n5. The target aneurysm is a blister aneurysm, dissecting aneurysm, mycotic (infectious) aneurysm, ruptured aneurysm, or aneurysm caused by connective tissue diseases;\n6. Severe vascular stenosis or tortuosity, or anatomical anomalies where it is anticipated that the device will be difficult to navigate to the lesion site, or other uncommon anatomies that may interfere with device use;\n7. The target vessel has undergone any previous embolization therapy or surgical intervention, or has recurrent disease;\n8. Definite allergy, resistance, or contraindication to antiplatelet drugs, anticoagulants, contrast media, and\u002For anesthetics;\n9. Females who are pregnant, breastfeeding, or planning to become pregnant within 6 months; males planning for parenthood within the next 6 months;\n10. Subjects currently participating in other drug or device clinical trials who have not reached the trial endpoint;\n11. Investigators deem the subject unsuitable for participation in this study.","18 Years","75 Years",{"count":65,"type":19},139,"INTERVENTIONAL",[68],"NA","Evaluation of the Safety and Effectiveness of the Peripheral Embolization Coil System Manufactured by Suzhou Zhongtian Medical Instruments Co., Ltd. for the Treatment of Arteriovenous Embolization in the Peripheral Vasculature in a Real-World Setting",[71,23,72,73],"Peripheral Arterial Hemorrhage","Arteriovenous Fistula","Peripheral Aneurysm","2025-09-04",{"date":76,"type":47},"2025-09-05",{"date":78,"type":19},"2025-09",{"date":80,"type":19},"2026-12",{"name":82,"class":54},"Suzhou Zenith Vascular Scitech Co., Ltd.",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":15,"minAge":62,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":113},"100602063","clinical-study-on-emergency-treatment-of-cerebral-arteriovenous-malformation-bleeding-100602063","NCT07118631","Clinical Study on Emergency Treatment of Cerebral Arteriovenous Malformation Bleeding","Clinical Study on Emergency Treatment of Cerebral Arteriovenous Malformation Bleeding and Continuous Improvement of Medical Quality Based on Neurosurgery Hybrid Surgery Platform","Inclusion Criteria:\n\n* Head CT confirmed cerebral hemorrhage, with indications for emergency surgery\n* Head CTA suggested that the responsible lesion may be cerebral arteriovenous malformation\n* Spetzler-Martin classification 1 to 4; Cerebral arteriovenous malformation Spetzler-Martin classification is as follows: ① Nidus size: small (\\\u003C3 cm) is scored as 1 point, medium (3 cm\\~6 cm) is scored as 2 points, and large (≥6 cm) is scored as 3 points; ② Adjacent brain functional areas: 0 points for non-functional areas, 1 point for functional areas; ③ Drainage veins: 0 points for superficial veins, 1 point for deep veins);\n* Aged 18 to 70 years old, with systemic conditions that can tolerate surgery;\n* Agree to surgical treatment and sign an informed consent form.\n\nExclusion Criteria:\n\n* Consciousness disorder due to serious underlying diseases\n* Patients or family members who refuse surgery\n* Perinatal and pregnancy patients","70 Years",{"count":92,"type":19},162,"Cerebral arteriovenous malformation (AVM) is the leading cause of brain hemorrhage in young adults, characterized by sudden onset and rapid progression. The hybrid neurosurgical operating room is a diagnostic and therapeutic platform that integrates neurointervention and microneurosurgery, offering advantages such as one-stop rapid treatment and multimodal therapeutic approaches.\n\nThis study aims to focus on patients with acute cerebral AVM-related hemorrhage through a multicenter, prospective, registry-based research approach. In the hybrid neurosurgical operating room, emergency cerebral angiography, neurointerventional embolization, microsurgical resection of the vascular malformation, or minimally invasive hematoma evacuation will be performed to explore the indications and advantages of the hybrid neurosurgical operating platform in emergency AVM hemorrhage management. The study seeks to establish standardized diagnostic and treatment protocols and operational workflows for emergency AVM hemorrhage management in the hybrid operating room. Through continuous quality improvement, the study aims to further reduce patient morbidity and mortality.\n\nThis research will not only enhance the diagnostic and therapeutic level of cerebral AVM-related hemorrhage and improve patient outcomes but also effectively reduce medical costs and societal burdens.",[23,95],"Bleeding",[97,98,99,100,101],"Cerebral hemorrhage","cerebral arteriovenous malformation","hybrid surgery","functional prognosis","quality improvement system","RECRUITING","2025-08-11",{"date":105,"type":47},"2025-08-12",{"date":107,"type":47},"2025-04-01",{"date":109,"type":19},"2028-01-31",{"name":111,"class":112},"Beijing Tiantan Hospital","OTHER",1,{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":15,"minAge":62,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":123,"conditions":124,"keywords":128,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":113},"100592502","diagnostic-imaging-of-vascular-malformations-using-msot-and-ulm-100592502","NCT06994260","Diagnostic Imaging of Vascular Malformations Using MSOT and ULM","Multispectral Optoacoustic Tomography (MSOT) and Ultrasound Localization Microscopy (ULM) as Diagnostic Imaging for Lymphatic, Venous and Arteriovenous Malformations","Inclusion Criteria:\n\n* Confirmed vascular malformations (arteriovenous, venous, or lymphatic).\n* ≥18 years old and able to give their consent\n\nExclusion Criteria:\n\n* No imaging for diagnostic confirmation has been performed or is planned.\n* Lack of written consent\n* \\\u003C18 years old\n* Safety concerns of the study physician (a patient with physical, psychological, or psychiatric conditions that, in the opinion of the study physician, could compromise the patient's safety or the quality of the data, thereby making the patient an unsuitable candidate for the study).",{"count":122,"type":19},15,"This clinical study evaluates the efficacy and accuracy of Multispectral Optoacoustic Tomography (MSOT) and Ultrasound Localization Microscopy (ULM) for imaging and diagnosing vascular malformations (venous, arteriovenous, lymphatic). The study aims to enhance diagnostic precision and improve treatment planning through advanced non-invasive imaging techniques.",[125,23,126,127],"Vascular Malformation","Lymphatic Malformation","Venous Malformations",[125,129,23,126,130,131],"Venous Malformation","MSOT","ULM","2025-06-20",{"date":134,"type":47},"2025-06-22",{"date":136,"type":19},"2025-08-01",{"date":138,"type":19},"2026-06-01",{"name":140,"class":112},"University Hospital Erlangen",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":15,"minAge":62,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":66,"phases":151,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":165},"100270235","phase-2-proton-radiotherapy-for-primary-central-nervous-system-tumours-in-adults-100270235","NCT02797366","Proton Radiotherapy for Primary Central Nervous System Tumours in Adults","Proton Radiotherapy for Primary Central Nervous System Tumours in Adults - a Prospective Swedish Multicentre Study","PRO-CNS","Inclusion criteria:\n\n* The patient must be at least 18 years old\n* World Health Organization (WHO)\u002F Eastern Cooperative OncologyGroup (ECOG) performance status 0-2, Karnofsky score ≥60.\n* The patient must be able to understand the information about the treatment and give a written informed consent to participate in the trial.\n* Adequate follow-up study must be possible; this will exclude a patient who is uncooperative.\n* Must have a life expectancy of at least 3 years based on age and co-morbidities as well as diagnosis. For patients considered for re-irradiation the life expectancy must be estimated to minimum 6 months.\n* Must have a pathology proven CNS tumour or if not possible, the radiology findings must be evaluated at a multi-disciplinary conference at a university hospital.\n* Women of reproductive potential must agree to use an effective method of contraception during therapy such as an intrauterine device or condom. Pregnancy IS not an ineligibility criteria if radiotherapy is indicated and can-not be postponed.\n* Prior CNS radiotherapy is not an ineligibility criteria but re-irradiated patients will be included in a subgroup evaluated separately.\n\nPatients discussed at multidisciplinary conferences at one of the seven university hospitals in Sweden and found candidates for radiotherapy and one of following diagnoses:\n\n* Anaplastic glioma grade III with Loss of Heterozygosity (LOH) 1p\u002F19q and isocitrate dehydrogenase-1 (IDH-1) mutation\n* Arteriovenous malformations (AVMs)\n* Chordomas and chondrosarcomas\n* Craniopharyngiomas\n* Ependymomas\n* Intracranial germ cell tumours\n* Low grade gliomas - grade I-II\n* Medulloblastoma, Primitive neuroectodermal tumour (PNET)\n* Meningiomas\n* Neurocytoma\n* Other grade I-II primary CNS tumour according to WHO classification\n* Pituitary adenomas\n* Schwannomas\n* Spinal tumours\n* Whenever craniospinal irradiation (CSI) is indicated\n* Whenever re-irradiation of CNS is considered\n\nExclusion criteria:\n\n* Concomitant or previous malignancies. Exceptions are adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, or in situ carcinoma of the cervix uteri with a follow-up time of at least 3 years, or other previous malignancy with a disease-free interval of at least 5 years.\n* Not able to understand information or manage tests according to study protocol. If necessary, only authorized interpreters may be used to assist in the translation.\n* Psychiatric or addictive disorders or other medical conditions that, in the opinions of the investigator, would preclude the patient from meeting the study requirements.",{"count":150,"type":19},500,[152],"PHASE2","Open label, multi-centre prospective study. Adult patients with primary central nervous system tumours fulfilling the inclusion criteria according to the study protocol. The study consists of 2 sequential cohorts evaluated consecutively for the feasibility, safety and toxicity, as well as long-term survival data, when using spot scanning proton beam therapy.",[155,23],"Central Nervous System Tumour","2016-06-07",{"date":158,"type":19},"2016-06-13",{"date":160,"type":4},"2015-08",{"date":162,"type":19},"2030-07",{"name":164,"class":112},"Uppsala University",6]